CSL expects to move all of its current U.S. plasma centers to Haemonetics' collection system by the end of 2027. Haemonetics did not change its guidance and will quantify the impact in November.
Haemonetics' shares jumped on a single sentence about a customer's plans. The company has not yet said what the sentence is worth.
In a filing before the open, the blood and plasma equipment maker said CSL "expects to complete the rollout" of its NexSys PCS plasma collection system with Persona PLUS technology "by the end of calendar year 2027," and "currently anticipates that the transition ... will occur at all of CSL's current U.S. plasma collection centers." CSL is one of the world's largest plasma collectors.
Haemonetics traded at $118.76 in early afternoon, up about 16.8%, close to its 52-week high of $120.72. The move added about $775 million to its market value, which now stands near $5.4 billion.
What is not in the filing
The filing does not estimate revenue, margins or unit volumes. Haemonetics said it is "not updating its previously issued fiscal 2027 guidance" and will discuss the expected impact on its fiscal second-quarter call in November. It also said the scope and timing of the rollout "remain subject to change."
The underlying contract, disclosed in August, is non-exclusive and contains no minimum purchase commitments, according to the company's filing at the time. That means CSL's stated plan is an expectation rather than a contractual volume guarantee.
Scale of the plan
Thursday's filing turns a supply agreement into a full-fleet plan. A transition across every current U.S. CSL center would make the customer's entire domestic collection network dependent on Haemonetics' devices and the disposable kits used in each collection.
The investor debate
One reading is that the market is pricing a durable stream of disposable-kit revenue from one of the industry's largest operators, and that a full transition by 2027 offers more visibility than the August agreement alone.
Another reading is that investors are paying in advance for figures the company has deliberately withheld, under a contract with no minimum purchases, from a customer whose plans can still change.
November's call
Haemonetics' fiscal second-quarter report in November will put the first numbers on the rollout, including any change to guidance. Any disclosure from CSL on timing or center count would serve as an independent check.